Skip to main content
OpenTrials
Completed

NCT Number: NCT03682237

Optimizing Metabolic Control in Type 1 Diabetes - The Automatic Bolus Calculator Flash Study

This study aims to compare the effect of flash glucose monitoring (FGM) with traditional self-monitoring of blood glucose (SMBG) with or without carbohydrate counting and automated bolus calculation, in patients with type 1 diabetes and poor metabolic control.

The investigators will include in total 200 patients recruited from 5 clinical sites in the Capital Region of Copenhagen.

The patients will be randomized into four groups; A) Standard diabetes training, i.e. group training in in general diabetes health issues, B) Group training in carbohydrate counting and automated bolus calculation, the app MySugr will be taught and downloaded, C) Group training as in group A, and instructed to use FGM, D) Group training as in group B, and besides training in the use of the app MySugr, also instructed to use FGM.

All patients are followed for 26 weeks with 6 clinical visits, group training (1 visit) and 2 telephone consultations.

The primary outcome is time spent in normoglycemia.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Mellitus, Type 1 Autoimmune Diseases Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Hyperglycemia Hypoglycemia Immune System Diseases Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Steno Diabetes Center Copenhagen

Copenhagen, Denmark

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age >/= 18 years
  • HbA1c > 53 mmol/mol
  • Type 1 diabetes more than 1 year
  • Treated with basal and bolus insulin. Basal insulin can be taken once or twice daily. The percentage basal/bolus insulin should as judged by the investigator cover the patient's real need for basal insulin - if he or she is not eating and taking bolus
  • Patients may or may not have knowledge on carbohydrate counting
  • Patients may or may not have any experience with continuous glucose monitoring or FGM
  • Patients have a personal smart phone
  • Patients attend the outpatient clinic in one of the five study sites included in the study

Exclusion criteria

  • Use of an automatic bolus calculator on a daily basis within the last three months
  • Daily use of continuous glucose monitoring or FGM on a daily basis within the last three months
  • Use of insulin pump
  • Use of Neutral Protamine Hagedorn insulin as long acting insulin (Insulatard, Humulin Retard) within the last three months
  • Pregnant, breastfeeding, plan to get pregnant
  • Gastroparesis
  • Severe diabetes complications including proliferative retinopathy and myocardial infarction within the last six months
  • Other concomitant medical or psychological condition that according to the investigator's assessment makes the patient unsuitable for study participation as e.g. alcohol and drug abuse
  • Current participation in another diabetes-related clinical trial that, in the judgment of the principle investigator, will compromise the results of the study or the safety of the subject
  • Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period or within 30 days prior to study start
  • Inability to understand the individual information and to give informed consent

Treatment and study plan

Carbohydrate counting, automated bolus calculation

Device

Group training in carbohydrate counting and bolus calculation. The app MySugr will be taught and downloaded on own smart phone and person specific parameters will be estimated and entered in the app with the patients. SMBG measures at least 4 times daily with patients own preferred glucose meter.

Flash glucose monitoring (FGM)

Device

Group training, patients will be instructed to use unblinded FGM for the whole study period. Patients are recommended to measure SMBG according to FGM manufactures guideline and handling of trend arrows etc.

Primary outcomes

  1. Time in normoglycemia

    Time frame: 26 weeks

    Difference in time in normoglycemic range 4-10 mmol/l at end of study measured by 2 weeks blinded FGM between group A (control group) and C (FGM) (min/day).

Secondary outcomes

  1. HbA1c

    Time frame: 26 weeks

    Difference among groups in change in HbA1c (mmol/mol).

  2. Severe hypoglycemia

    Time frame: 26 weeks

    Difference among groups in occurrence of severe hypoglycemia (defined as an event requiring assistance of another person. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal) (number of events during study period).

  3. Hypoglycemia

    Time frame: 26 weeks

    Difference among groups in occurrence of symptomatic and confirmed hypoglycemia (< 3 mmol/l) (number of episodes per week).

  4. Diabetes distress

    Time frame: 26 weeks

    Difference in changes in diabetes distress by the use of Problem Areas in Diabetes Questionnaire (PAID, score 0-100; higher scores reflecting diabetes distress).

  5. Diabetes treatment satisfaction

    Time frame: 26 weeks

    Difference in changes in treatment satisfaction by the use of Diabetes Treatment Satisfaction Questionnaire (DTSQ, score 0-36; higher scores reflecting higher satisfaction).

  6. Diabetes empowerment

    Time frame: 26 weeks

    Difference in changes in empowerment by the use of Diabetes empowerment test (DES-short form, containing 8 items, higher scores reflecting diabetes-related psychosocial self-efficacy. An item checked "strongly agree" receives 5 points; "agree" - 4 points; "neutral" - 3 points; "disagree" - 2 points; and "strongly disagree" receives 1 point, and an overall score is calculated by adding all of the scores (8-40) and dividing by the number of completed items (highest number is 8)).

  7. Diabetes quality of life

    Time frame: 26 weeks

    Difference in changes in life quality by the use of Diabetes quality of life (ADDQoL-19, scores -9-3, lower scores reflecting maximum negative impact).

  8. Blinded FGM hypoglycemia

    Time frame: 26 weeks

    Difference in change in time spent in hypoglycemia (<3mmol/l, <4 mmol/l) (min/day) from baseline (2 weeks) to end of study (2 weeks) in the different study groups.

  9. Blinded FGM hyperglycemia

    Time frame: 26 weeks

    Difference in change in time spent in hyperglycemia (>10 mmol/l) (min/day) from baseline (2 weeks) to end of study (2 weeks) in the different study groups.

  10. Blinded FGM glycemic variability

    Time frame: 26 weeks

    Difference in change in glycemic variability (standard deviation) from baseline (2 weeks) to end of study (2 weeks) in the different study groups.

  11. Personality traits

    Time frame: 26 weeks

    Association between personality traits evaluated by the use of Neuroticism Extraversion Openness Agreeableness Conscientiousness Five-Factor Inventory-3 (NEO-Five Factors Inventory-3) questionnaire and any other outcome measures in the different groups. The NEO-Five Factors Inventory-3 covers five factors/domains that describe the commonly accepted personality traits. The inventory contains 60 statements that should be evaluated by self-ratings on a 5-point scale where 1 reflects "strongly disagree" and 5 reflects "strongly agree". The answers are related to the norm and based on these scores, personality traits are reported by the internet based Hogrefe Testsystem 5 (Hogrefe Publishing Group).

  12. Total insulin dose

    Time frame: 26 weeks

    Difference in change between the groups in total insulin dose (units/day/kg) recorded as a mean of 2 weeks during FGM blinded measurements.

  13. Total basal insulin dose

    Time frame: 26 weeks

    Difference in change between the groups in total basal insulin dose (units/day/kg) recorded as a mean of 2 weeks during FGM blinded measurements.

  14. Insulin boluses

    Time frame: 26 weeks

    Difference in change between the groups in number of insulin boluses per day (number/day) recorded as a mean of 2 weeks during FGM blinded measurements.

  15. Body weight

    Time frame: 26 weeks

    Difference among groups in body weight (kg).

  16. Urinary albumin/excretion rate

    Time frame: 26 weeks

    Difference among groups in urinary albumin/excretion rate (mg/24 hours).

Sponsors and collaborators

Lead sponsor

Steno Diabetes Center Copenhagen

Other

Collaborators

  • Amager Hospital
  • Bispebjerg Hospital
  • Frederiksberg University Hospital
  • Hillerod Hospital, Denmark
  • Hvidovre University Hospital
  • Rigshospitalet, Denmark

Registry information

Official study title

Optimizing Metabolic Control in Type 1 Diabetes With Multiple Daily Insulin Injections - Flash Glucose Monitoring, Carbohydrate Counting With Automated Bolus Calculation, or Both?

Important dates

Study start
2018
Primary completion
2020
Study completion
2020
First posted
Sep 24, 2018
Registry last updated
Oct 28, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.